Sumeet Gandhi1, Wassim Mosleh2, Umesh C Sharma2, Catherine Demers3, Michael E Farkouh4, Jon-David Schwalm3. 1. McMaster University, Hamilton Health Sciences, Population Health Research Institute, Hamilton, Ontario, Canada. Electronic address: sumeet.gandhi@medportal.ca. 2. University of Buffalo, Buffalo, New York, USA. 3. McMaster University, Hamilton Health Sciences, Population Health Research Institute, Hamilton, Ontario, Canada. 4. Peter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Heart failure (HF) clinics (HFCs) are an integral aspect of the strategy for community HF care. METHODS: A systematic search was conducted to retrieve studies. We searched for candidate articles in the PubMed, EMBASE, and Cochrane databases from 1990 to January 2017. RESULTS: We included 16 randomized controlled trials in the meta-analysis with 3999 patients. The HFC group had a lower incidence of the primary composite end point of HF hospitalization and all-cause mortality (odds ratio [OR], 0.58; P = 0.0003). The benefit was maintained when stratified according to non-nurse led HFCs (OR, 0.52; P = 0.003), clinics that followed-up patients ≥ 3 months (OR, 0.51; P = 0.0009), patients with mean ejection fraction ≤ 30% (OR, 0.39; P = 0.02), and ejection fraction > 30% (OR, 0.72; P = 0.02), and patients with recent hospitalization for HF (OR, 0.51; P = 0.0001). There was no benefit in patients who were seen in HFCs with limited follow-up ≤ 3 months (OR, 0.91; P = 0.69), patients with stable HF without recent hospitalization (OR, 0.95; P = 0.70), and studies published after 2008 (OR, 0.89; P = 0.31). Patients in the HFC group had lower HF hospitalization rates (OR, 0.68; P = 0.003), however, no significant difference in all-cause hospitalization (OR, 1.04; P = 0.33). There was lower all-cause mortality in the HFC group (OR, 0.71; P = 0.006). CONCLUSIONS: The results of our analysis show a benefit of HFC to reduce HF hospitalization, and all-cause mortality. This was a cumulative benefit of all randomized clinical trials that assessed the benefit of HFC, with additional analysis showing a greater benefit among patients with recent emergency room visit or hospitalization, and patients seen frequently in follow-up ≥ 3 months.
BACKGROUND:Heart failure (HF) clinics (HFCs) are an integral aspect of the strategy for community HF care. METHODS: A systematic search was conducted to retrieve studies. We searched for candidate articles in the PubMed, EMBASE, and Cochrane databases from 1990 to January 2017. RESULTS: We included 16 randomized controlled trials in the meta-analysis with 3999 patients. The HFC group had a lower incidence of the primary composite end point of HF hospitalization and all-cause mortality (odds ratio [OR], 0.58; P = 0.0003). The benefit was maintained when stratified according to non-nurse led HFCs (OR, 0.52; P = 0.003), clinics that followed-up patients ≥ 3 months (OR, 0.51; P = 0.0009), patients with mean ejection fraction ≤ 30% (OR, 0.39; P = 0.02), and ejection fraction > 30% (OR, 0.72; P = 0.02), and patients with recent hospitalization for HF (OR, 0.51; P = 0.0001). There was no benefit in patients who were seen in HFCs with limited follow-up ≤ 3 months (OR, 0.91; P = 0.69), patients with stable HF without recent hospitalization (OR, 0.95; P = 0.70), and studies published after 2008 (OR, 0.89; P = 0.31). Patients in the HFC group had lower HF hospitalization rates (OR, 0.68; P = 0.003), however, no significant difference in all-cause hospitalization (OR, 1.04; P = 0.33). There was lower all-cause mortality in the HFC group (OR, 0.71; P = 0.006). CONCLUSIONS: The results of our analysis show a benefit of HFC to reduce HF hospitalization, and all-cause mortality. This was a cumulative benefit of all randomized clinical trials that assessed the benefit of HFC, with additional analysis showing a greater benefit among patients with recent emergency room visit or hospitalization, and patients seen frequently in follow-up ≥ 3 months.
Authors: Ian G Stiell; Lisa Mielniczuk; Heather D Clark; Guy Hebert; Monica Taljaard; Alan J Forster; George A Wells; Catherine M Clement; Jennifer Brinkhurst; Erica L Brown; Marie-Joe Nemnom; Jeffrey J Perry Journal: CJEM Date: 2021-01-04 Impact factor: 2.410
Authors: Òscar Miró; V Íctor Gil; Francisco Javier Martín-Sánchez; Javier Jacob; Pablo Herrero; Aitor Alquézar; Lluís Llauger; Sira Aguiló; Gemma Martínez; José Ríos; Alberto Domínguez-Rodríguez; Veli-Pekka Harjola; Christian Müller; John Parissis; W Frank Peacock; Pere Llorens Journal: Clin Res Cardiol Date: 2018-03-28 Impact factor: 5.460
Authors: Òscar Miró; Koji Takagi; Étienne Gayat; Víctor Gil; Pere Llorens; Francisco J Martín-Sánchez; Javier Jacob; Pablo Herrero-Puente; Rosa Escoda; María Pilar López-Díez; Amparo Valero; Marta Fuentes; José M Garrido; Eva Salvo; Miguel A Rizzi; Alfons Aguirre; Lissete Travería Bécquer; Alberto Domínguez-Rodríguez; Joan Padrosa; Gemma Martínez; Mattia Arrigo; Yonathan Freund; Alexandre Mebazaa Journal: Clin Res Cardiol Date: 2019-04-29 Impact factor: 5.460
Authors: Pupalan Iyngkaran; Andrew Wilson; James Wong; David Prior; David Kaye; David L Hare; Peter Bergin; Michael Jelinem Journal: Curr Cardiol Rev Date: 2021